Company intelligence / Profile preview

My Viva

Shanghai, Shanghai, Chinadiscover.myvivaplan.com ↗

Ownership: Private
Employees: ~2063
Development stage: Commercial

Overview

Viva Biotech provides comprehensive CRO/CDMO services from early-stage structure-based drug discovery through commercial manufacturing. It supports global biotech and pharma companies with advanced technology platforms and expertise in both small molecules and biologics. The company also invests in high-potential startups via an equity-for-service model. No direct clinical results reported as it is primarily a service provider.

Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugatePeptidesRecombinant proteinFusion proteinPlasmid DNALive biotherapeutic product therapy
Industry: Drug Discovery Services

Partnerships

Temasek, Highlight Capital, True Light invested in 2023 ($210M)Numerous partnerships with global biotech/pharma companies via CRO/CDMO contracts

Beyond the preview

Go deeper on My Viva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on My Viva.

Explore the full profile